Evaluation of the applicability of GARDskin to predict skin sensitizers in extracts from medical device materials
Biocompatibility testing of medical devices is governed by the ISO 10993 series of standards and includes evaluation of skin sensitization potential of the final product. A majority of all medical devices are tested using in vivo methods, largely due to the lack of in vitro methods validated within...
Main Authors: | Rose-Marie Jenvert, Olivia Larne, Angelica Johansson, Mattias Berglin, Emma Pedersen, Henrik Johansson |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-03-01
|
Series: | Frontiers in Toxicology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/ftox.2024.1320367/full |
Similar Items
-
The “Big Three” in biocompatibility testing of medical devices: implementation of alternatives to animal experimentation—are we there yet?
by: Helena Kanďárová, et al.
Published: (2024-01-01) -
Toxic or not toxic? The specifications of the standard ISO 10993-5 are not explicit enough to yield comparable results in the cytotoxicity assessment of an identical medical device
by: Sarah Gruber, et al.
Published: (2023-06-01) -
ISO 10993 biological evaluation of novel hemostatic powder – 4SEAL®
by: Lukasz Szymanski, et al.
Published: (2022-04-01) -
In Vivo Analysis of the Regeneration Capacity and Immune Response to Xenogeneic and Synthetic Bone Substitute Materials
by: James Bielenstein, et al.
Published: (2022-09-01) -
Strategy to Avoid Skin Sensitization: Application to Botanical Cosmetic Ingredients
by: Mickaël Puginier, et al.
Published: (2022-04-01)